John Ford (Enterprise)
Roche joins AbbVie in stepping on Vertex's turf, betting $96M on an alternative CF approach
James Sabry’s latest deal spree is taking Roche back to a field where Genentech nabbed one of its first FDA approvals: cystic fibrosis.
Turning to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
